Biocon Limited — Important, 21-05-2025: General Updates

Biocon Biologics and partner Yoshindo have expanded access to their Ustekinumab biosimilar in Japan, enhancing treatment options for psoriasis and psoriatic arthritis. This move strengthens Biocon’s footprint in key global biosimilar markets and complements existing launches in the US and Europe, bolstering growth in high-value specialty biosimilars.